"Pfizer's Seagen Acquisition Boosts Earnings Despite Covid Slump"

Pfizer's recent earnings report showed mixed results, with a beat on earnings per share but a miss on revenue expectations, leading to disappointment on Wall Street. CEO Albert Bourla believes the company's $43 billion acquisition of Seagen, an oncology company specializing in antibody drug conjugates (ADCs), will provide the next big opportunity for growth. The acquisition is seen as a way to fill revenue gaps from patent expirations and provide a potential blockbuster pipeline. Despite investor disappointment, analysts are optimistic about Pfizer's future, especially with Seagen's drug Padcev expected to bring in $3.1 billion this year.